N8Medical has entered into a CRADA with USAMRIID in support of Core Antibiotic Screening Program. Will test CSAs against biodefense
Latest News
News
News
FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a
N8 Medical News
Here you will find the latest information, including: press releases, events and presentations and blog posts.
Newsletter Sign-up
Interested in hearing whats new with N8 Medical? Sign-up to join our newsletter.
Recent Posts
- N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens
- FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF
- NIH Awards N8 Medical Two Additional SBIR Grants to Develop CeraShieldTM Coated Hemodialysis Catheters and Pedicle Screws
- N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant
- N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes
Contact us
Lets Get in Touch!
- info@n8medical.com
- N8 Medical, LLC1090 Center DrivePark City, UT 84098
Follow now
mynewform
Basic contact form
N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.